Amy Paller, MD, Discusses Long-Term Safety and Efficacy of Ixekizumab in Kids

Paller discusses the findings of the clinical trial examining the long-term effects of ixekizumab for treating psoriasis in children.

Related Videos
Related Content

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

No Increase of Serious Infection Risk From Systemic Medications in Pediatric Psoriasis Treatment

March 14th 2023

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

No Increase of Serious Infection Risk From Systemic Medications in Pediatric Psoriasis Treatment

March 14th 2023

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023

Air Pollution from Wildfire Smoke Can Exacerbate Skin Conditions

March 24th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

September 23rd 2021

No Increase of Serious Infection Risk From Systemic Medications in Pediatric Psoriasis Treatment

March 14th 2023

New Positive Results of Oral IL-23 Receptor Antagonist for Psoriasis

March 7th 2023
© 2023 MJH Life Sciences

All rights reserved.